|
|
|
LifeScienceHistory.com - Check us out on Instagram
Take Your Next Career Step with Lundback
California Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing CaliforniaLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Raptor Pharmaceutical Corp.
| | | Phone: | (415) 382-8111 | Fax: | (415) 382-1368 | Year Established: | 2005 | Ticker: | HZNP | Exchange: | NASDAQ | Main Contact: | Thomas E. "Ted" Daley, CBO | | Other Contacts: | David Happel, CCO Kimberly Lee, VP, Corporate Strategy & Communications Todd C. Zankel, Ph.D., CSO & Co-Founcer Kim R. Tsuchimoto, VP, International Finance, Tax and Treasury Paul K. Ross, VP, Chief Compliance Officer Krishna R. Polu, M.D., CMO Patrick Reichenberger, VP, Strategic Development Kathy L. Powell, Chief Quality Officer Eric B. Mosbrooker, VP, US Commercial Operations Henk Doude van Troostwijk, GM, European Commercial Operations Patrick Donahue, VP, Business Development Julie Anne Smith, President & CEO-designate Michael P. Smith, CFO
| | Company Description | Raptor Pharmaceutical is a global biopharmaceutical company focused on the development and commercialization of life-altering therapeutics that treat rare, debilitating and often fatal diseases. The company is engaged in multiple therapeutic areas such as nephropathic cystinosis, Huntington's disease (HD), nonalcoholic steatohepatitis (NASH), Leigh syndrome and other mitochondrial diseases. With PROCYSBI approved in the U.S. and EU, Raptor also holds several orphan drug designations, including exclusivity for nephropathic cystinosis in the U.S. and EU, and orphan drug designation for HD in the U.S. A request for EU orphan designation for RP103 in HD has been submitted. A request for orphan designation for Leigh syndrome has been submitted to the FDA. Raptor holds intellectual property for the use of cysteamine in HD and other neurodegenerative disorders including Parkinson's disease and Rett syndrome.
On Oct. 25, 2016, Horizon Pharma and Raptor Pharmaceutical announced Horizon Pharma had completed it acquisition of all issued and outstanding shares of Raptor common stock for $9.00 per share in cash, for an implied fully diluted equity value of $800 million. | |
|
|
|
|
|